These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33722440)

  • 1. SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF.
    Zhao LM; Ding LL; Zhan ZL; Qiu M
    Eur J Intern Med; 2021 May; 87():102-103. PubMed ID: 33722440
    [No Abstract]   [Full Text] [Related]  

  • 2. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter-2 inhibitors: where and when?
    Cowie MR
    Future Cardiol; 2021 May; 17(3):403-406. PubMed ID: 33586477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors in people with and without T2DM.
    Khunti K
    Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
    [No Abstract]   [Full Text] [Related]  

  • 6. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
    Singhal R; Hechanova LA
    Curr Cardiol Rep; 2022 Mar; 24(3):183-189. PubMed ID: 35147891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
    Qiu M; Ding LL; Zhan ZL; Zhou HR
    Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
    [No Abstract]   [Full Text] [Related]  

  • 8. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
    Yu B; Dong C; Hu Z; Liu B
    Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases].
    Lu H; Hullin R; Yerly P; Meyer P; Kosinski C; Daux A
    Rev Med Suisse; 2021 May; 17(740):1034-1038. PubMed ID: 34042339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
    Wanner C; Marx N
    Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction.
    Patoulias D; Papadopoulos C; Doumas M
    Eur J Intern Med; 2021 May; 87():100-101. PubMed ID: 33632595
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are SGLT2 Inhibitors Ready for Prime Time for CKD?
    Pecoits-Filho R; Perkovic V
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):318-320. PubMed ID: 28893920
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do SGLT2 inhibitors protect elderly patients from HF rehospitalization and CKD progression? More opportunities than concerns.
    Galassi A; Cara A; Magagnoli L; Faccioli FM; Cozzolino M
    Int J Cardiol; 2023 Jan; 370():321-322. PubMed ID: 36341998
    [No Abstract]   [Full Text] [Related]  

  • 17. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin.
    Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jun; 20(6):1367-1368. PubMed ID: 29377537
    [No Abstract]   [Full Text] [Related]  

  • 18. [Important alteration of the Dutch treatment algorithm in patients with type 2 diabetes mellitus].
    Serné EH; IJzerman RG; Krijger-Dijkema JM; Burger KNJ; Hart HE; Klein Woolthuis EP; Janssen PGH; Wiersma T
    Ned Tijdschr Geneeskd; 2021 Nov; 165():. PubMed ID: 35138747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV; Mather PJ
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-glucose cotransporter-2 inhibitors: Use in patients with chronic kidney disease.
    Falk J; Klarenbach S; Lam C; Potter J
    Can Fam Physician; 2022 Oct; 68(10):753. PubMed ID: 36241403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.